Interstitial Cystitis Drugs Market Research Report Information By Drug Class (Non-steroidal Anti-inflammatory Drugs, Tricyclic Antidepressants, Pentosan Polysulfate Sodium (Elmiron), Dimethyl Sulfoxide (DMSO), Others), By Type (Non-ulcerative, Ulcerative), By Route of Administration (Oral, Intravesical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

Global Interstitial Cystitis Drugs Market Overview

Interstitial Cystitis Drugs Market Size was valued at USD 26.2 Billion in 2022. The Interstitial Cystitis Drugs market industry is projected to grow from USD 27.6 Billion in 2023 to USD 41.3 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.20% during the forecast period (2023 - 2032). The growing population of the elderly and increasing technological progress are the key market drivers boosting the expansion of the market.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Interstitial Cystitis Drugs Market Trends

Growing number of interstitial cystitis cases is driving the market growth

Market CAGR for interstitial cystitis drugs is being driven by increasing interstitial cystitis prevalence. Interstitial cystitis (IC), also known as painful bladder syndrome, is a persistent bladder problem that is frequently accompanied by lower back, pelvic, or lower abdomen pain in addition to bladder pressure and discomfort. The degree of pain the patient feels could be minor to severe.

Additionally, interstitial cystitis (IC), sometimes referred to as bladder discomfort syndrome, is a chronic or long-lasting condition that causes uncomfortable symptoms when urinating. Different symptoms might be experienced by people with IC. For instance, certain people don't feel much pressure, pain, or discomfort in the pelvic area. Urinary urgency, or the sudden need to urinate, or frequency, or the urge to urinate more frequently, may be significant bladder discomfort for others. The rising incidence of interstitial cystitis in today's world is one of the key factors driving the market's growth rate. Women are more susceptible to this illness. Endometriosis, fibromyalgia, and allergies are typical side effects. The daytime and nighttime clinical manifestations of interstitial cystitis include urgency, frequency, and pelvic pain.

Given that IC is more prevalent in women and typically manifests in middle life, the aging  population is more susceptible to the ailment. It is anticipated that demand for IC-related goods and treatments will increase as a result of a demographic trend toward an older population.Advances in diagnostic methods such as hydrodistention, biomarker identification, and cystoscopy have improved the early identification and treatment of IC. This makes prompt intervention and therapy possible. Neuromodulation and intravesical treatment are among the more therapeutic options that are now available to individuals with IC thanks to advancements in medical equipment and minimally invasive treatments.

For instance, the National Center for Biotechnology Information published a report estimating the annual incidence rate of interstitial cystitis in the United States to be 2.6 cases per 100,000 women annually. The report also indicated that the prevalence of the condition was 18 cases per 100,000 women in Europe, while only 3–4 cases per 100,000 women are reported annually in Japan. Thus, result in driving the Interstitial Cystitis Drugs market revenue.

Interstitial Cystitis Drugs Market Segment Insights

Interstitial Cystitis Drugs Drug Class Insights

The  Interstitial Cystitis Drugs market segmentation, based on drugs class includes non-steroidal anti-inflammatory drugs, tricyclic antidepressants, pentosan polysulfate sodium (Elmiron), dimethyl dulfoxide (DMSO) and others. The pentosan polysulfate sodium (Elmiron) segment dominated the market. Due to the increasing prevalence of interstitial cystitis, the pentosan polysulfate sodium (Elmiron) segment is anticipated to have a significant position in the worldwide interstitial cystitis medications market throughout the forecast period.

Interstitial Cystitis Drugs Type Insights

The  Interstitial Cystitis Drugs market segmentation, based on type, includes Non-ulcerative, Ulcerative. The ulcerative segment generated the most income. Due to the increasing number of clinical trials that industry participants are starting to treat patients with interstitial cystitis, the ulcerative category is anticipated to have a dominating position in the  interstitial cystitis medicines market over the forecast period.

Interstitial Cystitis Drugs Route of Administration Insights

The  Interstitial Cystitis Drugs market segmentation, based on Route of Administration includes Oral, Intravesical. The oral segment dominated the market. Because more major players in the market are launching new products, the oral segment is anticipated to lead the market over the projected time.

Interstitial Cystitis Drugs Distribution Channel Insights

The  Interstitial Cystitis Drugs market segmentation, based on Distribution Channel includes Hospital Pharmacies, Retail Pharmacies, Online Pharmacies. The hospital pharmacies segment dominated the market. Due to the growing number of hospitals around the world, which will inevitably increase demand for hospital pharmacies, hospital pharmacies are predicted to dominate the market during the projection period.

Figure1: Interstitial Cystitis Drugs Market, by Distribution channel,2022&2032(USD Billion)

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Interstitial Cystitis Drugs Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American Interstitial Cystitis Drugs market area will dominate this market, owing to an increase the growth of the local market will be assisted by an increase in research spending.

Further, the major countries studied in the market report are The US, German, France, the UK, Canada, Italy, Spain, India, Australia, South Korea, China, Japan, and Brazil.

Figure2: Interstitial Cystitis Drugs Market Share By Region 2022 (USD Billion)

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Europe Interstitial Cystitis Drugs market has the second-largest portion of the market due to the Infrastructure changes in the healthcare system can lead to improved identification and treatment of interstitial cystitis. Further, the German Interstitial Cystitis Drugs market had the biggest market share, and the UK Interstitial Cystitis Drugs market was the fastest growing market in the European region

The Asia-Pacific Interstitial Cystitis Drugs Market is anticipated to expand between 2023 and 2032 at the quickest CAGR. This is due to aging population contributes to the increased prevalence of diseases related to the bladder. Moreover, China’s Interstitial Cystitis Drugs market had the biggest market share, and the Indian Interstitial Cystitis Drugs market was the fastest growing market in the Asia-Pacific region.

Interstitial Cystitis Drugs Key Market Players& Competitive Insights

Leading market players are putting a lot of money on R&D to expand their product lines, which will help the market for weight reduction products grow. Additionally, market players are engaging in a range of calculated initiatives to increase their worldwide presence, with important market developments involving the introduction of new products, contracts, M&A transactions, increased investment, and cooperation with other enterprises. to grow and endure in an increasingly cutthroat and dynamic market, Interstitial Cystitis Drugs industry must provide reasonably priced goods.

Manufacturing locally is one of the primary business techniques used by manufacturers to cut operational costs in the  Interstitial Cystitis Drugs industry to help customers and expand the market segment. In recent years, the Interstitial Cystitis Drugs industry has provided some of the biggest benefits to medicine. Major players in the Interstitial Cystitis Drugs market, including AbbVie Inc., Hyloris Pharmaceuticals SA, TAGCyx Biotechnologies, KYORIN Pharmaceutical Co., Ltd., PureTech Health, Vaneltix, Red Leaf Medical Inc., Bayer AG, Eli Lilly and Co, Johnson & Johnson (Janssen.

The American pharmaceutical business AbbVie Inc. has its main office in North Chicago, Illinois. According to revenue, it is placed sixth among the biggest biomedical enterprises. The company's main offering, injectable Humira (adalimumab) ($21 billion in revenues in 2022, or 37% of total), is its main product. It is authorized for the treatment of autoimmune conditions such as ulcerative colitis, rheumatoid arthritis, Crohn's disease, and plaque psoriasis. In June 2019, AbbVie declared that it will pay approximately $63 billion to acquire the Irish company Allergan plc; however, the deal would not be set up as a tax inversion, and AbbVie would continue to have its legal domicile in the United States after the transaction.] The business sold off a few assets to get FTC permission.

One of the biggest pharmaceutical and biomedical corporations in the world is Bayer AG, a multinational pharmaceutical and biotechnology firm based in Germany. Bayer, who has its headquarters in Leverkusen, is a company that deals in pharmaceuticals, consumer healthcare goods, seeds, agricultural chemicals, and biotechnology products. The business is included in the EURO STOXX 50 index of stock market companies. In July 2020, While denying the appeal, the California Court of Appeals lowered the amount of damages due to $20.4 million.[203] About 165,000 claims against Roundup had been lodged as of 2023; over 50,000 of those claims were still ongoing. The majority of the claims claimed that Roundup was the cause of cancer.

Key Companies in the Interstitial Cystitis Drugs market include.

• AbbVie Inc.


• Hyloris Pharmaceuticals SA


• TAGCyx Biotechnologies


• KYORIN Pharmaceutical Co.


• PureTech Health


• Vaneltix, Red Leaf Medical Inc.


• Bayer AG


• Eli Lilly and Co


• Johnson & Johnson


• Mylan NV (Viatris Inc.)


• Perrigo Co. Plc, Pfizer Inc.


• Seikagaku Corp.


• Sun Pharmaceutical Industries Ltd.


• Teva Pharmaceutical Industries Ltd.


• ImprimisRx (Harrow Health, Inc.

Interstitial Cystitis Drugs Industry Developments

July 2020: A co-promotion agreement was announced by UCB and Ferring Pharmaceuticals Inc. to promote the CIMZIA prefilled syringe formulation for interstitial cystitis.

August 2021: Interstitial Cystitis/Bladder Pain Syndrome: Imbrium Treatments, a clinical-stage biopharmaceutical business, has exercised its license option to LYT-503/IMB-150. This was announced by PureTech, a clinical-stage biological therapies company. Imbrium Therapeutics already paid PureTech US$ 6.5 million, and in addition to royalties from product sales, PureTech might receive up to US$ 53 million in extra milestone payments for this program.

Mayy 2023: The pharmaceutical company Vaneltix Pharma, Inc. and the system integration and analytics software company Prevail Infoworks, Inc. collaborated to launch a clinical trial that is presently in Phase 2 and actively seeking patients to investigate the safety and effectiveness of VNX001 in subjects with IC/BPS in comparison to its individual components (lidocaine and heparin) or placebo.

Interstitial Cystitis Drugs Market Segmentation

Interstitial Cystitis Drugs Drug Class Outlook

• Non-steroidal anti-inflammatory drugs


• tricyclic antidepressants


• Pentosan polysulfate sodium (Elmiron)


• Dimethyl dulfoxide (DMSO)


• Others

Interstitial Cystitis Drugs Type Outlook

• non-ulcerative


• ulcerative

Interstitial Cystitis Drugs Route of Administration Outlook

• Oral


• intravesical

Interstitial Cystitis Drugs Distribution Channel Outlook

• hospital pharmacies


• retail pharmacies


• online pharmacies

Interstitial Cystitis Drugs Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  

• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America